Compare FSI & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | XBIT |
|---|---|---|
| Founded | 1991 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.2M | 74.4M |
| IPO Year | 2000 | 2015 |
| Metric | FSI | XBIT |
|---|---|---|
| Price | $6.30 | $2.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.1K | ★ 27.1K |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,494,325.00 | N/A |
| Revenue This Year | $63.39 | N/A |
| Revenue Next Year | $43.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.22 | $2.09 |
| 52 Week High | $11.48 | $3.61 |
| Indicator | FSI | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 39.06 |
| Support Level | $5.89 | $2.26 |
| Resistance Level | $6.67 | $2.69 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 52.08 | 10.34 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The company also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.